Differentially expressed genes identified in human melanoma cell lines with different metastatic behaviour using high density oligonucleotide arrays

Melanoma Research

Volumn 12, Issue 1, 2002, Pages 57-69

  De Wit, N J W ^a   Burtscher, H J ^b   Weidle, U H ^b   Ruiter, D J ^a   Van Muijen, G N P ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ROCHE DIAGNOSTICS GMBH   (Germany)

Author keywords

Differential expression; Melanoma; Oligonucleotide arrays; Tumour progression

Indexed keywords

ALPHA 2 MACROGLOBULIN; APOLIPOPROTEIN C2; ELONGATION FACTOR 1; ELONGATION FACTOR 2; PROTEIN SERINE THREONINE KINASE; SUBTILISIN; TRANSFORMING GROWTH FACTOR BETA; TYROSINASE RELATED PROTEIN 1;

ARTICLE; CANCER CELL CULTURE; CANCER INCIDENCE; CANCER SURGERY; CONTROLLED STUDY; DNA MICROARRAY; GENE EXPRESSION; GENE IDENTIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALIGNANT TRANSFORMATION; MELANOMA; METASTASIS; NORTHERN BLOTTING; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

BLOTTING, NORTHERN; DNA, COMPLEMENTARY; DOWN-REGULATION; HUMANS; MELANOMA; NEOPLASM METASTASIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, COMPLEMENTARY; SKIN NEOPLASMS; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 0036188940     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-200202000-00009     Document Type: Article

References (28)

1. Lifetime risk for development of skin cancer in the US population: Current estimate is now 1 in 5
2. The state-of-the-art in chemoprevention of skin cancer
3. Cutaneous melanoma
4. Tumor thickness, level of invasion and node dissection in stage I cutaneous melanoma
5. Gene expression profiles in normal and cancer cells
6. T-cell recognition of melanoma-associated antigens
7. Molecular classification of cutaneous malignant melanoma by gene expression profiling
8. Genomic analysis of metastasis reveals an essential role for RhoC
9. CTp11, a novel member of the family of human cancer/testis antigens
10. Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression
11. Analysis of Pmel17/gp100 expression in primary human tissue specimens: Implications for melanoma immuno- and gene-therapy
12. Expression of epidermal growth factor receptor in human cultured cells and tissues: Relationship to cell lineage and stage of differentiation
13. Vascular density in melanoma xenografts correlates with vascular permeability factor expression but not with metastatic potential
14. Decreased expression of both the low-density lipoprotein receptor-related protein/α (2)-macroglobulin receptor and its receptor-associated protein in late stages of cutaneous melanocytic tumor progression
15. Expression monitoring by hybridization to high-density oligonucleotide arrays
16. Proliferation and morphology of melanoma cells and benign human melanocytes under varying culture conditions
17. Molecular cloning of a human melanoma-associated chondroitin sulfate proteoglycan
18. MEMD, a new cell adhesion molecule in metastasizing human melanoma cell lines, is identical to ALCAM (activated leukocyte cell adhesion molecule)
19. Activated leukocyte cell adhesion molecule/CD166, a marker of tumor progression in primary malignant melanoma of the skin
20. Clonal variation in the production of tumor-associated alpha 2-macroglobulin in a malignant human melanoma and association with growth stimulation
21. Proteolysis in human breast cancer
22. Intact vitronectin induces matrix metalloproteinase-2 and tissue inhibitor of metalloproteinases-2 expression and enhanced cellular invasion by melanoma cells
23. Integrins and other adhesion molecules involved in melanocytic tumor progression
24. Cytoskeleton-associated proteins: Their role as cellular integrators in the neoplastic process
25. Neoplastic transformation is associated with coordinate induction of nuclear and cytoplasmic oxidative phosphorylation genes
26. CTL-defined cancer vaccines: Perspectives for active immunotherapeutic interventions in minimal residual disease
27. Novel immunologic approaches to the management of malignant melanoma